{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:50:54Z","timestamp":1791183054547,"version":"4.1.0"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Agence R\u00e9gionale de Sant\u00e9 Hauts de France and Agence Onco Hauts-de-France","award":["DOS\/SDES\/AR\/FIR\/2019\/282"],"award-info":[{"award-number":["DOS\/SDES\/AR\/FIR\/2019\/282"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>STUDY QUESTION<\/jats:title>\n                    <jats:p>Are young women with anti-M\u00fcllerian hormone (AMH) levels suggesting polycystic ovarian morphology (PCOM) at baseline better protected against chemo-induced ovarian damages?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SUMMARY ANSWER<\/jats:title>\n                    <jats:p>Compared with women with lower baseline AMH levels, women with pre-treatment AMH levels suggesting PCOM experienced a similar degree of follicular loss and only partial recovery of baseline values after treatment but maintained significantly higher AMH levels at 12 and 24\u2009months of follow-up and had a faster menstrual function resumption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WHAT IS KNOWN ALREADY?<\/jats:title>\n                    <jats:p>Longitudinal studies on AMH variations in women treated by chemotherapy have shown that pre-treatment AMH levels is one of the factors influencing the degree of the ovarian recovery. Recombinant AMH administration recently demonstrated a protective effect on ovarian follicles exposed to alkylating agents in mouse models. High AMH levels in women with polycystic ovaries have been associated with decreasing apoptosis of granulosa cells in small follicles and altered initial follicular growth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                    <jats:p>This retrospective analysis of prospective collected data was carried out at the OncoFertility Observatory of the Lille University Hospital from January 2012 to February 2022. All women eligible for chemotherapy are prospectively recruited for ovarian function indicators follow-up until 24\u2009months after the end of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                    <jats:p>467 women treated by alkylating agents for breast cancer (BC) or hematological malignancies (HM) were included in our Onco-Fertility Observatory and benefited from an onco-fertility consultation with discussion on fertility preservation options. The study population was divided into two groups according to basal AMH level at time of diagnosis: PCOM-like AMH levels \u226535\u2009pmol\/l before 2016 and \u2265 30\u2009pmol\/l after 2026 (PCOM group), and 8\u2009\u2265\u2009AMH &amp;lt;35\u2009pmol\/l (non-PCOM group). Serial AMH measurements were performed at baseline before chemotherapy initiation (AMH0), 15\u2009days after the start of chemotherapy (AMH1), 15\u2009days before the last chemotherapy cycle (AMH2), and at time 3, 6, 12, 18, and 24\u2009months from the end of chemotherapy. Menstrual function was assessed in parallel and antral follicle count (AFC) was performed at baseline, 12- and 24-month post-treatment. Serum AMH levels were measured using the second-generation enzyme immunoassay EIA AMH\/MIS kit from 2012 to 2016, and by an automated AMH immunoassay on an Access Dxi analyzer thereafter. Results were secondarily homogenized using a validated conversion formula.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                    <jats:p>261 BC women aged 31.4\u2009years, and 206 HM patients aged 24.4\u2009years eligible for alkylating regimen were included before commencing treatment. Sixty-six women in the BC population were excluded from this study (death n\u2009=\u20094, recurrence n\u2009=\u20097, lost to follow-up n\u2009=\u200955) and 81 in the HM population (death n\u2009=\u20096, lost of follow-up n\u2009=\u200946, pregnancies n\u2009=\u20092, oophorectomy for cryopreservation n\u2009=\u200927). A total of 195 BC and 125 HM patients completed the whole follow-up and were finally analyzed. In BC group, women with PCOM were significantly younger (P\u2009=\u20090.002), had a higher incidence of menstrual disturbances at baseline (P\u2009=\u20090.003) and had more frequently a hormone receptor-positive (HR+) tumor (P\u2009=\u20090.04). In HM group, PCOM women were not significantly different from non-PCOM women concerning general characteristics. In BC and HM groups, pre-treatment AFC was significantly higher in PCOM group versus non-PCOM (37.8\u2009\u00b1\u200914.7 vs 17.3\u2009\u00b1\u20099.4; P\u2009\u2264\u20090.001 and 33.6\u2009\u00b1\u200912.4 vs 19.3\u2009\u00b1\u20098.4; P\u2009\u2264\u20090.001, respectively). In BC, as in HM population, a depletion phase can be distinguished from the beginning to the end of chemotherapy (AMH0-AMH2) and a recovery phase from the end of chemotherapy (AMH2) to the time +12\u2009months followed by a sustaining phase between time +12 and 24\u2009months. In BC as in HM population, before and after adjustment for the confounding variables (age, BMI, smoking and oral contraceptive (OC) use prior to chemotherapy), AMH values in the PCOM group remained significantly higher at time +12 and +24\u2009months of follow-up. In BC PCOM subgroup, the AMH depletion slope was steeper and followed by a faster and higher AMH increase after the end of treatment, while no difference was observed between PCOM and non-PCOM HM women. In both cancer groups and in both subgroups of AMH levels, AMH values plateaued between Time +12 and Time +24\u2009months (adjusted mean difference in log AMH (95% CI) 0.2 (\u22120.2 to 0.5) in BC population; 0.5 (\u22120.1 to 1.1) in HM population). At the end of follow-up, the frequency of undetectable AMH values in BC was 8.3% in PCOM versus 30.4% in non-PCOM (P\u2009=\u20090.0072) whereas, in HM group, there was no significant difference (18.7% vs 29.9%; P\u2009=\u20090.55). In HM, only three women, all from the PCOM group, recovered their pre-treatment values at the end of follow-up. In BC, none of the women recovered their initial AMH values. Clinically, the incidence of persistent amenorrhea at time +12months in HM subgroup tended to be lower in PCOM than in non-PCOM women but did not reach significance (13.3% vs 30.4%; P\u2009=\u20090.22). In BC subgroup, the incidence of persistent amenorrhea was significantly higher in non-PCOM women at time +12\u2009months (2% vs 12%; P\u2009=\u20090.043) but no longer at time + 24\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                    <jats:p>the retrospective design of this study did not allow us to differentiate women with PCOS from women with PCOM only, as androgen levels were not routinely measured at baseline in this oncologic setting. The high incidence of women under OC at diagnosis (50%) may have underestimated the number of patients with AMH levels higher than 35\u2009pmol\/l. Two methods of AMH assays were used due to the long duration of the inclusion period but with validated and adapted cut-offs levels for the diagnosis of PCOM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                    <jats:p>Fertility preservation and biological\/clinical follow-up should be systematically offered to all women undergoing alkylating regimen, irrespective of their pre-treatment AMH level as very high ovarian follicular content does not preclude to significant follicle loss. A better understanding of the role of AMH in ovaries facing chemotherapy may ultimately help in developing ovarioprotective drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>FUNDING<\/jats:title>\n                    <jats:p>This work was supported by Agence R\u00e9gionale de Sant\u00e9 Hauts de France and Agence Onco Hauts-de-France who provided finances for AMH dosages (no. DOS\/SDES\/AR\/FIR\/2019\/282).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCLOSURES<\/jats:title>\n                    <jats:p>No competing interests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                    <jats:p>DC-2008-642 and CNIL DEC2015-112.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/humrep\/deag131","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:50:01Z","timestamp":1785930601000},"page":"1780-1789","source":"Crossref","is-referenced-by-count":0,"title":["Pre-treatment AMH levels suggesting PCOM do not prevent chemotherapy-induced ovarian damage despite higher long-term ovarian reserve: a longitudinal study in 467 women treated with alkylating agents"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8232-3959","authenticated-orcid":false,"given":"C","family":"Decanter","sequence":"first","affiliation":[{"name":"Academic ART and Fertility Preservation Centre, Jeanne de Flandre Hospital, Lille University Hospital , Lille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Legrand","sequence":"additional","affiliation":[{"name":"Academic ART and Fertility Preservation Centre, Jeanne de Flandre Hospital, Lille University Hospital , Lille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Behal","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Lille University Hospital , Lille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Mailliez","sequence":"additional","affiliation":[{"name":"Breast Cancer Unit, Medical Oncology Department, Centre Oscar Lambret , Lille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Cavalieri","sequence":"additional","affiliation":[{"name":"Department of Hematology, Lille University Hospital , Lille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"D\u2019Orazio","sequence":"additional","affiliation":[{"name":"Academic ART and Fertility Preservation Centre, Jeanne de Flandre Hospital, Lille University Hospital , Lille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3926-4487","authenticated-orcid":false,"given":"P","family":"Pigny","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Hormonology, Metabolism, Nutrition and Oncology, Lille University Hospital , Lille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"2026100501515698700_deag131-B1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.fertnstert.2017.11.012","article-title":"Differential rate in decline in ovarian reserve markers in women with polycystic ovary syndrome compared with control subjects: results of a longitudinal study","volume":"109","author":"Ahmad","year":"2018","journal-title":"Fertil Steril"},{"key":"2026100501515698700_deag131-B2","doi-asserted-by":"crossref","first-page":"hoaa052","DOI":"10.1093\/hropen\/hoaa052","article-title":"ESHRE guideline: female fertility preservation\u2020","volume":"2020","author":"Anderson","year":"2020","journal-title":"Hum Reprod Open"},{"key":"2026100501515698700_deag131-B3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/humupd\/dmac004","article-title":"Anti-M\u00fcllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review","volume":"28","author":"Anderson","year":"2022","journal-title":"Hum Reprod Update"},{"key":"2026100501515698700_deag131-B4","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S1470-2045(18)30500-X","article-title":"Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin\u2019s lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial","volume":"19","author":"Anderson","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026100501515698700_deag131-B5","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1016\/j.ejca.2013.07.014","article-title":"Pretreatment anti-M\u00fcllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer","volume":"49","author":"Anderson","year":"2013","journal-title":"Eur J Cancer"},{"key":"2026100501515698700_deag131-B6","doi-asserted-by":"crossref","first-page":"574263","DOI":"10.3389\/fendo.2020.574263","article-title":"The clinical value and interpretation of anti-M\u00fcllerian hormone in women with cancer","volume":"11","author":"Anderson","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026100501515698700_deag131-B7","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1093\/humrep\/del201","article-title":"The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer","volume":"21","author":"Anderson","year":"2006","journal-title":"Hum Reprod"},{"key":"2026100501515698700_deag131-B8","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.2217\/fon-2016-0176","article-title":"Chemotherapy-induced damage to ovary: mechanisms and clinical impact","volume":"12","author":"Bedoschi","year":"2016","journal-title":"Future Oncol"},{"key":"2026100501515698700_deag131-B9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/humrep\/deab232","article-title":"Substituting serum anti-M\u00fcllerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study","volume":"37","author":"Bell","year":"2021","journal-title":"Hum Reprod"},{"key":"2026100501515698700_deag131-B10","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1634\/theoncologist.2015-0044","article-title":"Long-term follow-up of chemotherapy-induced ovarian failure in young breast cancer patients: the role of vascular toxicity","volume":"20","author":"Ben-Aharon","year":"2015","journal-title":"Oncologist"},{"key":"2026100501515698700_deag131-B11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/09513590.2013.777415","article-title":"The role of serum anti-M\u00fcllerian hormone (AMH) in the hormonal diagnosis of polycystic ovary syndrome","volume":"29","author":"Casadei","year":"2013","journal-title":"Gynecol Endocrinol"},{"key":"2026100501515698700_deag131-B12","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1210\/jc.2007-1650","article-title":"Granulosa cell survival and proliferation are altered in polycystic ovary syndrome","volume":"93","author":"Das","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100501515698700_deag131-B13","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1093\/humrep\/deab189","article-title":"Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling","volume":"36","author":"Decanter","year":"2021","journal-title":"Hum Reprod"},{"key":"2026100501515698700_deag131-B14","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.rbmo.2009.11.010","article-title":"Anti-M\u00fcllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results","volume":"20","author":"Decanter","year":"2010","journal-title":"Reprod Biomed Online"},{"key":"2026100501515698700_deag131-B15","doi-asserted-by":"crossref","first-page":"104547","DOI":"10.1016\/j.breast.2025.104547","article-title":"Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial","volume":"83","author":"Demeestere","year":"2025","journal-title":"Breast"},{"key":"2026100501515698700_deag131-B16","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1210\/jc.2018-00724","article-title":"Does AMH relate to timing of menopause? results of an individual patient data meta-analysis","volume":"103","author":"Depmann","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100501515698700_deag131-B17","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/humupd\/dmt062","article-title":"The physiology and clinical utility of anti-M\u00fcllerian hormone in women","volume":"20","author":"Dewailly","year":"2014","journal-title":"Hum Reprod Update"},{"key":"2026100501515698700_deag131-B18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3389\/fendo.2020.00641","article-title":"Role of anti-M\u00fcllerian hormone in the pathogenesis of polycystic ovary syndrome","volume":"11","author":"Dewailly","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026100501515698700_deag131-B19","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1093\/humrep\/der297","article-title":"Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries","volume":"26","author":"Dewailly","year":"2011","journal-title":"Hum Reprod"},{"key":"2026100501515698700_deag131-B20","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/humupd\/dmw027","article-title":"Interactions between androgens, FSH, anti-M\u00fcllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary","volume":"22","author":"Dewailly","year":"2016","journal-title":"Hum Reprod Update"},{"key":"2026100501515698700_deag131-B21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2017.03.035","article-title":"Prospective evaluation of serum anti-M\u00fcllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer","volume":"79","author":"Dezellus","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026100501515698700_deag131-B22","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.fertnstert.2021.05.094","article-title":"Antim\u00fcllerian hormone to determine polycystic ovarian morphology","volume":"116","author":"Dietz de Loos","year":"2021","journal-title":"Fertil Steril"},{"key":"2026100501515698700_deag131-B23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.fertnstert.2012.09.039","article-title":"Pre-treatment AMH determines rate of post-therapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy","volume":"99","author":"Dillon","year":"2013","journal-title":"Fertil Steril"},{"key":"2026100501515698700_deag131-B24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.fertnstert.2020.08.011","article-title":"Utility of gonadotropin-releasing hormone agonists for fertility preservation in women receiving chemotherapy: pros and cons","volume":"114","author":"Dolmans","year":"2020","journal-title":"Fertil Steril"},{"key":"2026100501515698700_deag131-B25","doi-asserted-by":"crossref","first-page":"e1862","DOI":"10.1210\/clinem\/dgz283","article-title":"Antimullerian hormone and impending menopause in late reproductive age: the study of women\u2019s health across the nation","volume":"105","author":"Finkelstein","year":"2020","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"2026100501515698700_deag131-B26","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1093\/humrep\/dex239","article-title":"Use of the serum anti-M\u00fcllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome","volume":"32","author":"Fraissinet","year":"2017","journal-title":"Hum Reprod"},{"key":"2026100501515698700_deag131-B27","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.fertnstert.2011.10.040","article-title":"Impact of cancer therapies on ovarian reserve","volume":"97","author":"Gracia","year":"2012","journal-title":"Fertil Steril"},{"key":"2026100501515698700_deag131-B28","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.fertnstert.2012.08.008","article-title":"Low concentration of circulating antim\u00fcllerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study","volume":"98","author":"Hagen","year":"2012","journal-title":"Fertil Steril"},{"key":"2026100501515698700_deag131-B29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.rbmo.2015.12.008","article-title":"Anti-M\u00fcllerian hormone in breast cancer patients treated with chemotherapy: a retrospective evaluation of subsequent pregnancies","volume":"32","author":"Hamy","year":"2016","journal-title":"Reprod Biomed Online"},{"key":"2026100501515698700_deag131-B30","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.fertnstert.2010.04.006","article-title":"Correlation of ovarian reserve tests with histologically determined primordial follicle number","volume":"95","author":"Hansen","year":"2011","journal-title":"Fertil Steril"},{"key":"2026100501515698700_deag131-B31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.fertnstert.2025.07.030","article-title":"Temsirolimus and antim\u00fcllerian hormone protect fertility and the ovarian reserve against chemotherapy-induced damage in a murine model","volume":"125","author":"Houeis","year":"2026","journal-title":"Fertil Steril"},{"key":"2026100501515698700_deag131-B32","doi-asserted-by":"crossref","first-page":"185ra62","DOI":"10.1126\/scitranslmed.3005402","article-title":"Cyclophosphamide triggers follicle activation and \u201cburnout\u201d; as101 prevents follicle loss and preserves fertility","volume":"5","author":"Kalich-Philosoph","year":"2013","journal-title":"Sci Transl Med"},{"key":"2026100501515698700_deag131-B33","doi-asserted-by":"crossref","first-page":"16291","DOI":"10.3390\/ijms242216291","article-title":"Overactivation or apoptosis: which mechanisms affect chemotherapy-induced ovarian reserve depletion?","volume":"24","author":"Kashi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026100501515698700_deag131-B34","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/humrep\/dead064","article-title":"Dual suppression of follicle activation pathways completely prevents the cyclophosphamide-induced loss of ovarian reserve","volume":"38","author":"Kashi","year":"2023","journal-title":"Hum Reprod"},{"key":"2026100501515698700_deag131-B35","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12916-016-0699-y","article-title":"Back to the basics of ovarian aging: a population-based study on longitudinal anti-M\u00fcllerian hormone decline","volume":"14","author":"Kat","year":"2016","journal-title":"BMC Med"},{"key":"2026100501515698700_deag131-B36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/molehr\/gar059","article-title":"Data-driven assessment of the human ovarian reserve","volume":"18","author":"Kelsey","year":"2012","journal-title":"Mol Hum Reprod"},{"key":"2026100501515698700_deag131-B37","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.annonc.2020.09.006","article-title":"Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines\u2020","volume":"31","author":"Lambertini","year":"2020","journal-title":"Annals of Oncology"},{"key":"2026100501515698700_deag131-B38","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.fertnstert.2025.08.023","article-title":"Polycystic ovary syndrome: antim\u00fcllerian hormone and its role in the pathophysiology of the syndrome","volume":"124","author":"Laven","year":"2025","journal-title":"Fertil Steril"},{"key":"2026100501515698700_deag131-B39","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/humrep\/dex226","article-title":"Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-M\u00fcllerian hormone using cluster analysis","volume":"32","author":"Lie Fong","year":"2017","journal-title":"Hum Reprod"},{"key":"2026100501515698700_deag131-B40","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejogrb.2020.09.016","article-title":"Evolution of serum anti-M\u00fcllerian hormone (AMH) level in young women treated with chemotherapy for breast cancer according to basal AMH level","volume":"254","author":"Loubersac","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2026100501515698700_deag131-B41","doi-asserted-by":"crossref","first-page":"105118","DOI":"10.1016\/j.rbmo.2025.105118","article-title":"Factors influencing the rate of anti-M\u00fcllerian hormone decline: a retrospective study of 4245 infertile women","volume":"51","author":"Ma","year":"2025","journal-title":"Reprod Biomed Online"},{"key":"2026100501515698700_deag131-B42","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/ijc.33933","article-title":"Is ovarian recovery after chemotherapy in young patients with early breast cancer influenced by controlled ovarian hyperstimulation for fertility preservation or tumor characteristics? Results of a prospective study in 126 patients","volume":"150","author":"Mailliez","year":"2022","journal-title":"Int J Cancer"},{"key":"2026100501515698700_deag131-B43","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/GRF.0b013e3181f96b54","article-title":"Toxicity of chemotherapy and radiation on female reproduction","volume":"53","author":"Meirow","year":"2010","journal-title":"Clin Obstet Gynecol"},{"key":"2026100501515698700_deag131-B44","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1093\/humrep\/dem027","article-title":"Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury","volume":"22","author":"Meirow","year":"2007","journal-title":"Hum Reprod"},{"key":"2026100501515698700_deag131-B45","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/cncr.22199","article-title":"Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate","volume":"107","author":"Meirow","year":"2006","journal-title":"Cancer"},{"key":"2026100501515698700_deag131-B46","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/humupd\/dms022","article-title":"How do chemotherapeutic agents damage the ovary?","volume":"18","author":"Morgan","year":"2012","journal-title":"Hum Reprod Update"},{"key":"2026100501515698700_deag131-B47","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.fertnstert.2023.02.019","article-title":"Contraceptive-specific antim\u00fcllerian hormone values in reproductive-age women: a population study of 42,684 women","volume":"119","author":"Nelson","year":"2023","journal-title":"Fertil Steril"},{"key":"2026100501515698700_deag131-B48","doi-asserted-by":"crossref","first-page":"10159","DOI":"10.1158\/0008-5472.CAN-07-2042","article-title":"A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve","volume":"67","author":"Oktem","year":"2007","journal-title":"Cancer Res"},{"key":"2026100501515698700_deag131-B49","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1477-7827-12-26","article-title":"Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review","volume":"12","author":"Peign\u00e9","year":"2014","journal-title":"Reprod Biol Endocrinol"},{"key":"2026100501515698700_deag131-B50","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.fertnstert.2015.12.023","article-title":"Comparative assessment of five serum antim\u00fcllerian hormone assays for the diagnosis of polycystic ovary syndrome","volume":"105","author":"Pigny","year":"2016","journal-title":"Fertil Steril"},{"key":"2026100501515698700_deag131-B51","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.fertnstert.2025.05.147","article-title":"Prospective validation of anti-M\u00fcllerian hormone cutoff to determine polycystic ovarian morphology: HARMONIA study","volume":"124","author":"Piltonen","year":"2025","journal-title":"Fertil Steril"},{"key":"2026100501515698700_deag131-B52","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s10815-019-01507-9","article-title":"Pharmacological administration of recombinant human AMH rescues ovarian reserve and preserves fertility in a mouse model of chemotherapy, without interfering with anti-tumoural effects","volume":"36","author":"Roness","year":"2019","journal-title":"J Assist Reprod Genet"},{"key":"2026100501515698700_deag131-B53","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.fertnstert.2020.11.040","article-title":"Ovaries of patients recently treated with alkylating agent chemotherapy indicate the presence of acute follicle activation, elucidating its role among other proposed mechanisms of follicle loss","volume":"115","author":"Shai","year":"2021","journal-title":"Fertil Steril"},{"key":"2026100501515698700_deag131-B55","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1096\/fj.201801089R","article-title":"AMH prevents primordial ovarian follicle loss and fertility alteration in cyclophosphamide-treated mice","volume":"33","author":"Sonigo","year":"2019","journal-title":"Faseb J"},{"key":"2026100501515698700_deag131-B56","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1001\/jama.2017.14588","article-title":"Association between biomarkers of ovarian reserve and infertility among older women of reproductive age","volume":"318","author":"Steiner","year":"2017","journal-title":"Jama"},{"key":"2026100501515698700_deag131-B57","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1002\/cncr.28942","article-title":"Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients","volume":"120","author":"Su","year":"2014","journal-title":"Cancer"},{"key":"2026100501515698700_deag131-B58","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1210\/clinem\/dgaa172","article-title":"Modeling variation in the reproductive lifespan of female adolescent and young adult cancer survivors using AMH","volume":"105","author":"Su","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100501515698700_deag131-B59","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1200\/JCO-24-02782","article-title":"Fertility preservation in people with cancer: ASCO guideline update","volume":"43","author":"Su","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026100501515698700_deag131-B60","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/humrep\/dead156","article-title":"Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome\u2020","volume":"38","author":"Teede","year":"2023","journal-title":"Hum Reprod"},{"key":"2026100501515698700_deag131-B61","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0140-6736(03)14410-8","article-title":"Formation and early development of follicles in the polycystic ovary","volume":"362","author":"Webber","year":"2003","journal-title":"Lancet"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/41\/10\/1780\/70652913\/deag131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/41\/10\/1780\/70652913\/deag131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:52:10Z","timestamp":1791179530000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/41\/10\/1780\/8761809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":60,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,8,14]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deag131","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,8,14]]}}}